Yang Jung-Hyun, Lee Won-Suk, Kim Sang-Wook, Woo Sang-Uk, Kim Jeong-Han, Nam Seok-Jin
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Arch Surg. 2005 Feb;140(2):125-8. doi: 10.1001/archsurg.140.2.125.
Core-needle biopsy (CNB) and fine-needle aspiration (FNA) play an important role in the initial diagnosis of breast cancer. However, CNB might alter the size of the tumor, which might subsequently change its pathologic stage and thus affect the decision about adjuvant chemotherapy.
Between January 2000 and May 2002, we studied 291 patients with invasive carcinoma lesion in a retrospective analysis. One hundred ninety-nine patients underwent ultrasonography-guided CNB. Ninety-two patients had FNA before surgical manipulation.
The clinically measured tumor size using ultrasonography was compared with the pathologic tumor size in both the CNB and FNA groups. The difference in each group was determined and analyzed using a t test. The mean +/- SD preoperative ultrasonographically measured size in the CNB group was 2.09 +/- 1.06 cm and in the FNA group, 2.16 +/- 0.92 cm (no significant difference). The pathologic measurement of the lesion on surgical specimens revealed that the mean pathologic tumor size was 2.09 +/- 0.90 cm in the CNB group and 2.36 +/- 0.92 cm in the FNA group. The changes in size from preoperative measurements by ultrasonography to pathologic measurements on surgical specimens were greater in the CNB group (0.003 +/- 0.65 cm) than in the FNA group (0.20 +/- 0.39 cm; P = .001).
Although the reduction in tumor size might be small with patients who undergo CNB, it must be considered when deciding adjuvant treatment, especially for tumor sizes on the "borderline" in establishing the indication for and the type of adjuvant treatment.
粗针活检(CNB)和细针穿刺抽吸活检(FNA)在乳腺癌的初始诊断中发挥着重要作用。然而,CNB可能会改变肿瘤大小,进而可能改变其病理分期,从而影响辅助化疗的决策。
在2000年1月至2002年5月期间,我们对291例浸润性癌病变患者进行了回顾性分析。199例患者接受了超声引导下的CNB。92例患者在手术操作前进行了FNA。
比较CNB组和FNA组中通过超声临床测量的肿瘤大小与病理肿瘤大小。使用t检验确定并分析每组的差异。CNB组术前超声测量的平均大小为2.09±1.06cm,FNA组为2.16±0.92cm(无显著差异)。手术标本上病变的病理测量显示,CNB组的平均病理肿瘤大小为2.09±0.90cm,FNA组为2.36±0.92cm。从术前超声测量到手术标本病理测量的大小变化在CNB组(0.003±0.65cm)中比在FNA组(0.20±0.39cm;P = 0.001)中更大。
尽管接受CNB的患者肿瘤大小的减小可能很小,但在决定辅助治疗时必须予以考虑,尤其是对于在确定辅助治疗的适应证和类型时处于“临界”大小的肿瘤。